Senti Biosciences

Senti Biosciences company information, Employees & Contact Information

Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance their therapeutic effectiveness against a broad range of diseases that conventional medicines do not readily address. For more information, please visit the Senti Bio website at https://www.sentibio.com.

Company Details

Employees
70
Founded
-
Address
2 Corporate Drive,
Email
co****@****bio.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
South San Francisco, CA
Looking for a particular Senti Biosciences employee's phone or email?

Senti Biosciences Questions

News

Senti Bio to Present at BioJapan - Yahoo Finance

Senti Bio to Present at BioJapan Yahoo Finance

Oct 21 live webcast: Senti Biosciences CEO to present at Chardan 9th Genetic Medicines Conference — 11:35 AM ET - Stock Titan

Oct 21 live webcast: Senti Biosciences CEO to present at Chardan 9th Genetic Medicines Conference — 11:35 AM ET Stock Titan

Oct 9, 11:30 JST — Senti Biosciences presents at BioJapan; CEO Timothy Lu to speak, booth D-53 - Stock Titan

Oct 9, 11:30 JST — Senti Biosciences presents at BioJapan; CEO Timothy Lu to speak, booth D-53 Stock Titan

Gene Circuit Platform Developer Senti Bio to Showcase Next-Gen Cell Therapy at MedInvest Conference - Stock Titan

Gene Circuit Platform Developer Senti Bio to Showcase Next-Gen Cell Therapy at MedInvest Conference Stock Titan

Senti Biosciences CEO Timothy Lu to Present at Chardan's 9th Annual Genetic Medicines Conference - Quiver Quantitative

Senti Biosciences CEO Timothy Lu to Present at Chardan's 9th Annual Genetic Medicines Conference Quiver Quantitative

Senti Biosciences Reports Positive Preliminary Data from Phase 1 Trial of SENTI-202 in Relapsed/Refractory AML at AACR Annual Meeting 2025 - Nasdaq

Senti Biosciences Reports Positive Preliminary Data from Phase 1 Trial of SENTI-202 in Relapsed/Refractory AML at AACR Annual Meeting 2025 Nasdaq

Gene Circuit Platform Developer Senti Bio to Showcase Latest Advances at H.C. Wainwright Conference - Stock Titan

Gene Circuit Platform Developer Senti Bio to Showcase Latest Advances at H.C. Wainwright Conference Stock Titan

Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar - Yahoo Finance

Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar Yahoo Finance

Senti Biosciences Announces Positive Data for SENTI-202 in Phase 1 Trial at AACR Annual Meeting 2025 - Nasdaq

Senti Biosciences Announces Positive Data for SENTI-202 in Phase 1 Trial at AACR Annual Meeting 2025 Nasdaq

FDA Backs Senti Bio Revolutionary Cancer Drug as 60% of AML Patients Face Critical Outcomes - Stock Titan

FDA Backs Senti Bio Revolutionary Cancer Drug as 60% of AML Patients Face Critical Outcomes Stock Titan

Senti Bio and Dynamics Special Purpose Corp. Announce - GlobeNewswire

Senti Bio and Dynamics Special Purpose Corp. Announce GlobeNewswire

Senti Bio Advances AML Treatment: Phase 2 Dose Confirmed, FDA Orphan Drug Status Secured - Stock Titan

Senti Bio Advances AML Treatment: Phase 2 Dose Confirmed, FDA Orphan Drug Status Secured Stock Titan

Exclusive: Senti Bio CEO Reveals Personal Journey and Strategic Vision for Gene Circuit Platform - Stock Titan

Exclusive: Senti Bio CEO Reveals Personal Journey and Strategic Vision for Gene Circuit Platform Stock Titan

Senti Bio Phase 1 Trial Shows 57% Complete Remission Rate in AML Treatment | SNTI Stock News - Stock Titan

Senti Bio Phase 1 Trial Shows 57% Complete Remission Rate in AML Treatment | SNTI Stock News Stock Titan

Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 - Stock Titan

Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 Stock Titan

Top Senti Biosciences Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant